Akanda Beheer
Beheer criteriumcontroles 1/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
Katie Field
Algemeen directeur
US$112.0k
Totale compensatie
| Percentage CEO-salaris | 100.0% |
| Dienstverband CEO | 1.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 2.2yrs |
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$32m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$112k | US$112k | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$24m |
| Jun 30 2023 | n/a | n/a | -US$12m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$70k | US$35k | -US$8m |
Compensatie versus markt: Katie's total compensation ($USD111.97K) is below average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Katie's compensation has increased whilst the company is unprofitable.
CEO
Katie Field (41 yo)
1.8yrs
Tenure
US$111,968
Compensatie
Ms. Katharyn Field, also known as Katie, serves as an Independent Chairman of the Board of iSpecimen Inc. since September 2024. She is Independent Director of Virpax Pharmaceuticals, Inc. from July 2024. M...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Interim CEO & Executive Director | 2.3yrs | US$111.97k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Chair of Advisory Board | 2.2yrs | geen gegevens | geen gegevens | |
| Independent Director | 2.3yrs | US$111.97k | geen gegevens | |
| Independent Director | 1.8yrs | US$79.95k | geen gegevens |
2.2yrs
Gemiddelde duur
43yo
Gemiddelde leeftijd
Ervaren bestuur: AKAN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.